Safety / interactions 2020

Lingzhi and Yunzhi + chemotherapy: a systematic review of medicinal-mushroom interactions with cytotoxic drugs

The first systematic review of medicinal-mushroom interactions with chemotherapy: 213 papers (77 clinical) on co-using reishi and turkey tail with cytotoxics. The headline — clinically significant pharmacokinetic interactions are essentially absent, but study quality is low and specific combination signals call for caution.

Chu K.K.W. et al. Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. Chin Med. 2020;15:75.

Why this study

Patients on chemotherapy often add "immune" mushrooms — reishi (Lingzhi) and yunzhi (Trametes versicolor/PSP-PSK). How their components interact with cytotoxics had barely been studied. This review is the first attempt to systematise all pharmacokinetic and pharmacodynamic data.

Methods

  • Search of 9 Chinese and English databases: clinical, animal and in-vitro work on co-administration with cytotoxics.
  • 213 studies found, 77 clinical (56 yunzhi, 21 lingzhi).
  • Clinical quality scored on the Jadad scale.

Findings

  • Pharmacokinetic interactions are barely documented: only 2 clinical PK studies — no significant effect on cytotoxic metabolism found.
  • Commonest combinations: with lingzhi — cisplatin, 5-FU, paclitaxel; with yunzhi — tegafur/UFT, 5-FU, mitomycin.
  • Clinical study quality is low (per Jadad); no hard contraindications were established either.

Limitations

  • Few human PK studies — cannot exclude simply unstudied interactions.
  • Extracts and doses vary — "reishi" means different preparations across authors.

Why it matters

The practical takeaway: don't reflexively add medicinal mushrooms to chemotherapy — but nor is there evidence for blanket prohibition. The review frames all our reishi/turkey-tail cards: "probably safe, evidence modest, talk to your oncologist."